Phase 3 clinical trial has been given approval by FDA
The FDA has given Ocugen permission to start their phase 3 gene therapy clinical trial for retinitis pigmentosa (RP).
Search
Search results
A week in the life of a researcher
On a typical week in the stem cell lab there are many different experiments going on. Different people work on their individual projects, but we often collaborate to share ideas and help each other.
Collective support from Sight Loss Charities
The cost-of-living crisis is having a major impact on the lives of blind and partially sighted people. Many people are becoming increasingly concerned about how they will make ends meet. Sight Loss Charities have come together as between us we can offer help and support.
Corporate partnerships
Our partnerships are mutually beneficial. For Retina UK this means we can fund more research and offer support on a local level, while our partners can achieve corporate social responsibility objectives whilst making a tangible impact.
Types of genetic testing
This page explains the different types of genetic tests: diagnostic testing, predictive testing, carrier testing and research testing
Amar Latif ‘delighted’ to be an ambassador for Retina UK
We are proud to announce that Amar Latif - adventurer, entrepreneur, TV presenter and public speaker - is to join Retina UK as a volunteer ambassador.
Meet our supporters: William Taylor
Fundraising for Retina UK means a lot to me - both my dad and my nephew have been affected by inherited sight-loss, and I've seen first-hand the incredible work this charity does.
Mirugen – Unlocking the Power of Retina Regeneration
Mirugen – Unlocking the Power of Retina Regeneration
Artificial vision
There are about 125 million rod and cone cells within the retina that act as the eye's light receptors.
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.